Bacterial Meningitis – Pipeline Review, 2019

Bacterial Meningitis, a type of meningitis, an infection caused in the membranes surrounding the brain and spinal cord of the body. Meningitis can be caused by bacteria, fungi, or a virus. Bacterial meningitis is the most serious type of meningitis. It can lead to death or permanent disability as the bacterial infection causes the brain tissue to swell, which then interferes with the blood flow resulting in paralysis or even stroke. Bacteria responsible for the meningeal cause are Streptococcus Pneumoniae, Group B Streptococcus, Hemophilus influenza, Listeria monocytogenes, and others. Symptoms of bacterial meningitis include high fever, headaches, and stiff neck. Other symptoms include nausea, vomiting, photophobia, and altered mental status.

Current treatment of bacterial meningitis includes the administration of antibiotics, corticosteroids, paracetamol, and others. Antibiotics such as asenicillin and cefotaxime are commonly used to treat bacterial meningitis as they kill bacteria and prevents the spread of infection in and around the brain tissues.

Pharmaceutical companies, along with various research institutes, have been focusing on studying and developing new treatment options for bacterial meningitis. For instance; DPT-IPV-Hib, which is being studied by Mitsubishi Tanabe Pharma Corporation is currently in phase-3 clinical trials for the study of safety, immunogenicity, and efficacy of DPT-IPV-Hib for protection against disease caused by meningococcal bacteria in infants.

At present, around 40% of the pipeline candidates for Bacterial Meningitis are in the phase-3 clinical study. Majority of studies for the treatment of bacterial meningitis are carried by research institutes.

Report Description

The report on ‘Bacterial Meningitis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Bacterial Meningitis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Bacterial Meningitis.

The report on ‘Bacterial Meningitis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Bacterial Meningitis.
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Bacterial Meningitis.
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary